Can You Take Trulicity and Wegovy Together?

Why can't GLP-1 medicines be combined?

Trulicity and Wegovy both activate GLP-1 (glucagon-like peptide-1) receptors. That shared mechanism is precisely why combining them creates a problem rather than a shortcut. You are not adding a second tool, you are pressing the same lever twice. The receptor does not have a second gear to unlock.

Practically, this means the gastrointestinal side effects common to both (nausea, vomiting, diarrhoea, stomach pain) are compounded rather than eliminated. The January 2026 MHRA Drug Safety Update on GLP-1 medicines specifically flags acute pancreatitis as a known risk with this drug class; suspected side effects can be reported via the MHRA Yellow Card scheme. Stacking two GLP-1 agents would make that kind of serious adverse outcome considerably more plausible.

There is also no evidence base for the combination. Regulatory approvals for both medicines are built on trials of each medicine alone, so prescribing them together would fall outside any licensed or guideline-supported framework. No responsible prescriber would do it, and if you are wondering whether Ozempic and semaglutide can be taken together, the answer follows the same logic, any platform offering both simultaneously without clinical review should be treated as a warning sign.

What is Trulicity actually licensed for, and how does that affect the picture?

Trulicity (dulaglutide, made by Eli Lilly) holds a UK licence for type 2 diabetes, not for weight management. Wegovy (semaglutide, made by Novo Nordisk) holds a UK licence specifically for weight management in eligible adults. The two products are sometimes discussed in the same breath because they share a mechanism and because weight loss is a common effect of GLP-1 medicines in general, but their indications, doses and clinical contexts differ.

If you are taking Trulicity for type 2 diabetes and want to switch to a weight-management medicine, that conversation involves your diabetes team as well as a weight-loss prescriber. Stopping a diabetes medicine without an alternative in place carries its own risks. The NHS patient guide to semaglutide gives a useful plain-English overview of how Wegovy works and what the prescribing considerations look like.

People sometimes ask about the relationship between dulaglutide and semaglutide in the same way they ask about combining Saxenda and Wegovy, the principle is the same across the class. Same receptor, same problem.

What does a proper switch from Trulicity to Wegovy actually look like?

A clinically supervised switch involves reviewing your current dose of Trulicity, understanding why the switch is being considered (better weight outcomes, intolerance, change in clinical needs), and then planning the timing carefully. There is generally no requirement for a lengthy wash-out period between GLP-1 agents because the class-effect on blood glucose needs to be managed continuously, but the specifics depend on the individual. That is not a generalisation you can safely rely on; it is a decision made case by case.

Wegovy starts at 0.25mg weekly and is titrated by a prescriber over several months, reaching a maintenance dose of 2.4mg (or, since the MHRA's April 2026 approval of the single-dose pen, potentially 7.2mg for eligible patients). The titration exists to let your system adjust, starting at the top of the range would not produce faster results, just more side effects.

If you are thinking about the cost of a switch, our Wegovy cost guide explains what private treatment realistically involves and why headline prices do not always reflect what you get. Worth a read before making any decisions.

For women on HRT, there is a separate set of considerations, our page on Wegovy and HRT covers what is known. The details of your own combination of medicines are always something to raise with your prescriber directly.

How do you find out if Wegovy is right for you after stopping Trulicity?

The eligibility criteria for Wegovy as a weight-management medicine are set out in its UK licence: adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. NICE's appraisal of semaglutide (TA875) sets out the conditions under which it is recommended within NHS specialist services.

For people accessing treatment privately, through a regulated online pharmacy, the process is different: a free consultation, reviewed the same working day by a GPhC-registered prescriber (a real clinician reading your answers, not automated triage), photo-ID and live weight verification, and same-day dispatch if you are clinically suitable and order before noon. We also cross-check for medicines that interact with semaglutide, including, specifically, whether you are currently on a GLP-1 agent like Trulicity.

If you have already switched, or you are mid-treatment and have questions about how Wegovy works alongside other parts of your routine, our prescribers are available seven days a week. You can also read our guide on whether MOTS-C and semaglutide can be taken together if you are exploring peptide combinations alongside your treatment. You can also explore our full weight-loss treatment options if you are still working out which path suits you. When you are ready, check your eligibility with a free consultation and a prescriber will review everything the same day.